BCMA Test Your Knowledge

Test Your Knowledge

Quiz: How Do Patients With MM Who Received Anti-BCMA Therapy Respond to COVID-19 Vaccinations?

12/01/2021

True or false: Patients with MM who received anti-BCMA antibody-based therapy were associated with having a lack of T-cell responses following SARS-CoV-2 vaccination.

True or false: Patients with MM...

12/01/2021

Oncology

Quiz

Quiz: Which of the Following Inhibitors Target BCMA in MM?

11/10/2021

Which of the following inhibitors showed an increase in BCMA surface density and a decrease in soluble BCMA levels?

Which of the following...

11/10/2021

Oncology

Test Your Knowledge

Quiz: Is Extramedullary Disease Associated with Poor Prognoses in R/R MM?

11/02/2021

True or false: In R/R MM, extramedullary disease is linked to significantly poor prognoses.

True or false: In R/R MM,...

11/02/2021

Oncology

Quiz

Quiz: Can Anti-BCMA CAR-T Cell Therapy Cause Humoral Immune Deficiencies in R/R MM?

10/14/2021

True or false: A profound and lasting humoral immune deficiency was found after anti-BCMA CAR-T cell therapy in patients with R/R MM.

True or false: A profound and...

10/14/2021

Oncology

Test Your Knowledge

Quiz: Which Cell Type is Known for BCMA Expression?

09/20/2021

Which of the following cell type is known for BCMA expression?

Which of the following cell type...

09/20/2021

Oncology

Test Your Knowledge

Quiz: Responses to BCMA-Directed CAR-T Therapy for R/R MM

09/07/2021

True or false: Results from the CARTITUDE-1 trial showed that BCMA-directed CAR-T therapy yielded early, deep, and durable responses in patients with R/R MM.

True or false: Results from the...

09/07/2021

Oncology

Test Your Knowledge

Quiz: Does Teclistamab Therapy Display Promise in BCMA-Positive MM?

11/19/2020

True or False: Data suggest that teclistamab is a promising therapy for patients with BCMA-positive MM.

True or False: Data suggest that...

11/19/2020

Oncology

Test Your Knowledge

Quiz: The Basics of BCMA Expression in Multiple Myeloma

10/08/2020

True or False: BCMA is expressed in nearly all MM tumor cells and serves as a potential biomarker for identifying malignant plasma cells in this patient population.

True or False: BCMA is expressed...

10/08/2020

Oncology

Test Your Knowledge

Quiz: Promising Role of BCMA-Directed CAR-T Therapy for R/R MM

09/25/2020

True or False: According to data from the CARTITUDE-1 trial, the BCMA-directed CAR-T therapy JNJ‑4528 was very effective and yielded 100% overall response rate in patients with relapsed or refractory MM.

True or False: According to data...

09/25/2020

Oncology

Test Your Knowledge

Quiz: Can BCMA-Targeting CAR T-Cells Improve Patient Outcomes in MM?

08/26/2020

True or False: Multiple studies have demonstrated positive results with BCMA-targeting CAR T-cells for the treatment of relapsed and refractory MM.

True or False: Multiple studies...

08/26/2020

Oncology

Recent News

News

Genotype-Guided Therapy Demonstrates High Response and Survival Rates for Patients With R/R DLBCL

09/26/2025

Emily Estrada

The implementation of R-ICE combined with genotype-guided therapy for the treatment of relapsed/refractory diffuse large B-cell lymphoma demonstrated clinical efficacy and safety in a phase 2 trial.

The implementation of R-ICE...

09/26/2025

Oncology

News

PD-1/PD-L1 Inhibitor Monotherapy Demonstrates Accceptable Safety, Limited Efficacy for R/R DLBCL

09/26/2025

Emily Estrada

Treatment of R/R diffuse large B-cell lymphoma with PD-1/PD-L1 inhibitors alone showed consistent safety but limited efficacy, while combination treatment with CAR T-cell therapy demonstrated potential improved outcomes.

Treatment of R/R diffuse large...

09/26/2025

Oncology

News

Polatuzumab-Based Regimens Demonstrate Promising Efficacy for R/R DLBCL Compared to Traditional Salvage Therapies

09/26/2025

Emily Estrada

Compared with traditional salvage therapies, polatuzumab vedotin and zanubrutinib combined with rituximab or obinutuzumab demonstrated encouraging clinical efficacy for patients with relapsed/refractory diffuse large B-cell lymphoma.

Compared with traditional...

09/26/2025

Oncology

FDA Approval

FDA Approves Imlunestrant for Patients With ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer

09/25/2025

Stephanie Holland

The FDA has approved imlunestrant for patients with ER-positive, HER2-negative advanced or metastatic breast cancer harboring ESR1 mutations.

The FDA has approved...

09/25/2025

Oncology

News

Pexidartinib Shows Durable Response Among Patients with Tenosynovial Giant Cell Tumors

09/25/2025

Allison Casey

Pexidartinib showed sustained clinical benefit among patients with tenosynovial giant cell tumor associated with severe morbidity or functional limitations and not amenable to surgery.

Pexidartinib showed sustained...

09/25/2025

Oncology

News

Clarithromycin-Based Quadruplet Therapy Demonstrates Promising Clinical Responses for Treatment of Relapsed/Refractory Multiple Myeloma

09/24/2025

Emily Estrada

For patients with relapsed/refractory multiple myeloma, the combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated promising clinical efficacy and a manageable safety profile.

For patients with...

09/24/2025

Oncology

News

First-Line mFOLFIRINOX, S-IROX Fail to Improve Survival Among Patients With Recurrent or Metastatic Pancreatic Cancer

09/23/2025

Stephanie Holland

Results from the phase 2/3 GENERATE study demonstrated that neither mFOLFIRINOX nor S-IROX improved survival results compared to nab-paclitaxel plus gemcitabine among patients with recurrent or metastatic pancreatic cancer in the first-line...

Results from the phase 2/3...

09/23/2025

Oncology

News

Novel Anti-CSF1 Receptor Antibody for Patients With Tenosynovial Giant Cell Tumor

09/23/2025

Allison Casey

According to a phase 2a trial, the novel anti-CSF1 receptor monoclonal antibody, AMB-05X, was found to have favorable pharmacokinetics, pharmacodynamics, efficacy, and safety among patients with tenosynovial giant cell tumors.

According to a phase 2a trial,...

09/23/2025

Oncology

News

Adverse Events With Pexidartinib for Patients With Tenosynovial Giant Cell Tumor

09/23/2025

Allison Casey

According to an analysis of the FDA Adverse Events Reporting System (FAERS) database, the overall safety profile of pexidartinib was generally consistent with the clinical trial findings.

According to an analysis of the...

09/23/2025

Oncology

News

Trifluridine/Tipiracil Plus Bevacizumab Escalation Demonstrates Promise Among Patients With Advanced or Unresectable Metastatic Colorectal Cancer

09/22/2025

Stephanie Holland

According to results from the phase 2 E-BiTS study, intrapatient escalation of biweekly trifluridine/tipiracil plus bevacizumab demonstrated promising efficacy and safety among patients with advanced or unresectable metastatic colorectal...

According to results from the...

09/22/2025

Oncology